Off-label use means taking an FDA-approved medication in a way that wasn’t part of its original approval. That could mean using it for a different condition, at a different dose, or in a different form than what appears on the drug’s official label. It’s legal, surprisingly common, and in many cases backed by solid clinical evidence, even if the FDA hasn’t formally signed off on that specific use.
What Counts as Off-Label
The FDA defines off-label use broadly. It covers three main scenarios: using a drug for a disease or condition it wasn’t approved to treat (like a cancer drug approved for one type of cancer being used for a different type), giving it in a different form (a capsule crushed into an oral solution, for example), or prescribing it at a different dose than what the label specifies.
The key distinction is between the drug itself and its label. The medication has passed FDA safety and manufacturing reviews. It’s an approved product. What hasn’t been reviewed is that particular use. No additional testing was submitted to the FDA, and no formal approval process was completed for the new indication, dose, or delivery method.
Why Doctors Prescribe This Way
Once the FDA approves a drug, healthcare providers can legally prescribe it for any use they judge to be medically appropriate for their patient. The FDA itself acknowledges this. Doctors aren’t breaking any rules, and in many clinical situations, off-label prescribing is standard practice rather than an unusual workaround.
The most common reason is simply that approved options don’t exist. Many conditions, particularly rare diseases and most childhood illnesses, have few or no drugs specifically approved for them. Pediatric medicine is a clear example: a study of major U.S. children’s hospitals found that 1 out of every 4 medications prescribed to kids was not in line with FDA label indications for the patient’s age. In inpatient pediatric settings, off-label rates climbed above 50%. Doctors treating these patients aren’t experimenting. They’re often following well-established clinical guidelines and published evidence that simply hasn’t gone through the formal (and expensive) FDA approval process for that specific population.
Other times, a drug’s mechanism of action makes it a logical fit for a related condition. Physicians may also turn to off-label options when a patient hasn’t responded to approved treatments, or when newer research supports a use that the manufacturer hasn’t pursued for approval.
What Drug Companies Can and Can’t Do
Here’s where the rules get stricter. While doctors are free to prescribe off-label, drug companies are prohibited from promoting their products for unapproved uses. The FDA regulates pharmaceutical marketing to ensure promotional materials aren’t false or misleading, and that includes banning companies from advertising a drug for conditions, populations, or dosing not on the approved label.
This distinction matters because it shapes what information reaches you. Your doctor might have strong clinical reasons to prescribe a medication off-label, but the manufacturer can’t be the one suggesting that use in its advertising or sales pitches to physicians. Violations of this rule have led to some of the largest pharmaceutical settlements in U.S. history, with companies paying billions in fines for illegally marketing drugs for off-label purposes.
Safety Considerations
Off-label use isn’t inherently dangerous, but it does carry a measurably higher risk of side effects compared to on-label use. Research tracking adverse drug events found that off-label prescriptions had a 44% higher rate of harmful reactions than on-label ones. When the off-label use lacked strong scientific evidence supporting it, that figure rose to 54%.
The quality of evidence behind a particular off-label use makes a real difference. Some off-label uses are supported by decades of clinical data and appear in major treatment guidelines. Others rest on limited case reports or small studies. The gap between those two categories shows up directly in patient outcomes. If your doctor prescribes something off-label, the strength of the supporting evidence is a reasonable thing to ask about.
Insurance Coverage for Off-Label Prescriptions
Whether your insurance will pay for an off-label prescription depends on the plan and the evidence behind the use. Medicare Part D, for instance, covers off-label drugs only if the use is identified as safe and effective in one of three officially recognized drug reference guides (called compendia). Only one of the three needs to list the use for Medicare to cover it.
For cancer drugs specifically, Medicare also accepts evidence from peer-reviewed medical journals to establish that an off-label use is medically appropriate. Private insurers often follow similar logic, requiring published evidence or guideline support before approving coverage. In practice, this means well-established off-label uses are frequently covered, while newer or less-studied ones may require prior authorization or an appeal.
What You’re Told (and Not Told)
You might assume your doctor is required to tell you when a prescription is off-label. In most cases, they aren’t. The FDA requires written consent for drugs used experimentally or as part of research, but no explicit consent is required for off-label prescribing in routine clinical care, as long as the doctor believes the drug is being used in your best interest.
Courts have generally sided with physicians on this point. In one notable ruling, a court determined that patients can’t assume from a label’s silence that a use recommended by their doctor is unsafe or untried. Legal requirements for informed consent also vary by state, adding another layer of inconsistency. Some jurisdictions require more disclosure than others.
The practical reality, as the American Medical Association has noted, is that current practice “does not require or even suggest that doctors disclose any of these facts to their patients.” That doesn’t mean you can’t ask. If you want to know whether a prescription is on-label or off-label, what evidence supports the use, and what alternatives exist, those are straightforward questions any prescriber should be willing to answer.